Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Emerging Infectious Diseases · 2024
DOI: 10.3201/eid3006.231454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Emerging Infectious Diseases, 2024. Verfasst von Ryo Kinoshita und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, COVID-19 Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Kinoshita, R., Miyamoto, S., Sakuraba, S., Sugihara, J., Suzuki, M., Suzuki, T., & Yoneoka, D. (2024). Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023. Emerging Infectious Diseases. https://doi.org/10.3201/eid3006.231454
Vancouver
Kinoshita R, Miyamoto S, Sakuraba S, Sugihara J, Suzuki M, Suzuki T, et al. Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023. Emerging Infectious Diseases. 2024. doi:10.3201/eid3006.231454
BibTeX
@article{Kinoshita2024,
author = {Kinoshita, Ryo and Miyamoto, Sho and Sakuraba, Shoko and Sugihara, Jun and Suzuki, Motoi and Suzuki, Tadaki and Yoneoka, Daisuke},
title = {Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023},
journal = {Emerging Infectious Diseases},
year = {2024},
doi = {10.3201/eid3006.231454}
}
EUVIMED